New Approaches to Neuroblastoma Therapy Consortium
24 clinical trials · Sponsor
◉ Watch New Approaches to Neuroblastoma Therapy Consortium
| Record | Firm | Date |
|---|---|---|
| NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab (NCT07261241) | New Approaches to Neuroblastoma Therapy Consortium | 2026-07-31 |
| NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial (NCT06450041) | New Approaches to Neuroblastoma Therapy Consortium | 2024-12-16 |
| Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells (NCT02573896) | New Approaches to Neuroblastoma Therapy Consortium | 2019-01-14 |
| MIBG With Dinutuximab +/- Vorinostat (NCT03332667) | New Approaches to Neuroblastoma Therapy Consortium | 2018-09-12 |
| NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) (NCT03107988) | New Approaches to Neuroblastoma Therapy Consortium | 2017-09-05 |
Track New Approaches to Neuroblastoma Therapy Consortium automatically
Every clearance here is in the API, with alerts when new ones post.